ABIONYX Pharma SA (EPA:ABNX)
France
· Delayed Price · Currency is EUR 3.540
-0.050 (-1.39%)
Apr 28, 2026, 5:35 PM CET
ABIONYX Pharma Revenue
In the year 2025, ABIONYX Pharma had annual revenue of 4.10M EUR, down -9.91%. ABIONYX Pharma had revenue of 1.98M in the half year ending December 31, 2025, a decrease of -21.14%.
Revenue
4.10M
Revenue Growth
-9.91%
P/S Ratio
30.46
Revenue / Employee
80.39K
Employees
51
Market Cap
124.88M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.10M | -451.00K | -9.91% |
| Dec 31, 2024 | 4.55M | -89.00K | -1.92% |
| Dec 31, 2023 | 4.64M | -612.00K | -11.65% |
| Dec 31, 2022 | 5.25M | 4.58M | 678.07% |
| Dec 31, 2021 | 675.00K | - | - |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Innate Pharma | 9.01M |
| MaaT Pharma | 4.52M |
| Adocia | 3.85M |
| Sensorion | 5.81M |
| Transgene | 7.21M |
| Valerio Therapeutics Société anonyme | 1.83M |
| OSE Immunotherapeutics | 1.78M |
| Cellectis | 67.79M |